Osteoporosis affects 30% of postmenopausal women globally, posing a major health burden. Existing treatments face safety and efficacy challenges, driving demand for innovative therapies. The pipeline includes anabolic agents, monoclonal antibodies, and small molecules. Growing interest in biologics and personalized medicine is expected to accelerate the development of next-generation ... https://www.expertmarketresearch.com/clinical-trials/osteoporosis-drug-pipeline-insight